Company Overview - The company, established in 2001, specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2] - It is a leading domestic manufacturer of non-invasive ventilators and masks, being the first domestic company to receive FDA certification for its non-invasive ventilator products [2] - The company has a well-rounded product line that includes home non-invasive ventilators, masks, sleep monitors, high-flow humidified oxygen therapy devices, and oxygen concentrators, and it offers chronic disease management services [2] Research and Development - The company maintains significant R&D investments, holding 666 valid domestic patents as of June 30, 2025, including 116 invention patents and 404 utility model patents [3] - It has also secured 266 overseas patents, including 45 in the United States and 38 in Europe [3] Financial Performance - For the first half of 2025, the company reported revenue of 544 million yuan, a year-on-year increase of 42.3%, and a net profit of 131 million yuan, also up 42.19% [11] - In Q2 2025, revenue reached 279 million yuan, reflecting a 46.54% year-on-year growth, with a net profit of 59.41 million yuan, up 39.92% [11] Profitability - The company's gross margin improved due to effective cost control and a higher proportion of sales from consumables, which have a higher gross margin [4] - The gross margin for the company was reported at 52.17% [11] Market Expansion - The company experienced significant growth in overseas markets, particularly in the United States, where revenue increased by 252.89% year-on-year [5] - Future plans include launching a new noise-reducing ventilator in the U.S. market and expanding into the European market with products entering mainstream insurance markets [6] Domestic Market Strategy - The company is transitioning smoothly to online channels while maintaining stable operations in the domestic market [9] - It plans to implement a multi-model product sales strategy for online self-operated channels and differentiate products for offline channels [9] Consumables Business - In the first half of 2025, consumables accounted for approximately 30% of the company's revenue, with expectations for continued growth driven by increased awareness and market penetration of ventilators [10]

Core Viewpoint - The report highlights that Ruimait (301367) has met performance expectations and is positioned to become a global leader in integrated respiratory devices, with a buy rating assigned for the first time [1] Group 1: Financial Performance - In 2024, the company achieved revenue of 843 million yuan, a year-on-year decrease of 24.85%, and a net profit attributable to shareholders of 155 million yuan, down 47.74% year-on-year [1] - In Q1 2025, the company reported revenue of 265 million yuan, an increase of 38.11% year-on-year, and a net profit of 72 million yuan, up 44.11% year-on-year [1] - The gross profit margins for 2023, 2024, and Q1 2025 were 46.14%, 48.34%, and 49.57%, respectively, indicating a steady upward trend [1] Group 2: Consumables Business Growth - The consumables segment is expected to achieve continuous growth, with revenue of 284 million yuan in 2024, reflecting a year-on-year increase of 46.22% [2] - The company is actively promoting its consumables in the U.S. market through a specialized team and a strategy of distributing masks for free at sleep monitoring institutions to enhance brand recognition [2] - In Europe, a data-oriented subsidiary was established in France in 2023 to address reimbursement issues and attract more partnerships, further expanding market reach [2] Group 3: Market Position and Expansion - The company is deeply engaged in the respiratory health sector, with a global market share of 12.4% for home non-invasive ventilators, ranking second globally and first among domestic brands in China with a market share of 30.6% [3] - As of 2024, the company's products are sold in over 100 countries and regions, having obtained multiple certifications including NMPA, FDA, and CE, making it one of the few domestic manufacturers to enter the U.S. and European healthcare markets [3] - A five-year exclusive distribution agreement was signed with RH in July 2024 to further penetrate the North American market [3] Group 4: Profit Forecast - Revenue forecasts for 2025, 2026, and 2027 are projected at 1.013 billion yuan, 1.268 billion yuan, and 1.610 billion yuan, respectively, with corresponding EPS of 2.60 yuan, 3.35 yuan, and 4.47 yuan [4] - The current stock price corresponds to PE ratios of 30.7, 23.8, and 17.9 for the years 2025, 2026, and 2027, respectively, indicating a favorable investment outlook [4]

Company Overview - Founded in 2001, the company launched its first multi-channel sleep monitor in 2003 and its first CPAP sleep breathing machine in 2007 [2] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2] - It is a leading domestic company in home non-invasive ventilators and masks, with products certified by NMPA, FDA, CE, and others, and sold in over 100 countries [2][3] Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company has 202 overseas patents, including 39 in the USA and 30 in Europe [3] Supply Chain and Production - The company has achieved basic localization of core components, ensuring supply chain security and cost advantages [4] - It operates two production facilities in Dongguan and Tianjin, with the ability to dynamically adjust production capacity based on market demand [5] Brand Strategy - The recent rebranding to "Resmart" signifies a strategic alignment between product and capital markets, enhancing brand value and recognition [5][6] - The name "Resmart" combines "respiratory" and "smart," reflecting the company's commitment to respiratory health and innovative technology [5] Market Performance - The domestic business showed positive performance in Q1, with revenue and gross margin improvements due to adjustments in channel strategies [6] - The company has established a strong global market presence, having entered the healthcare insurance markets in the USA, Germany, UK, France, and Italy [6] Investor Relations - The investor relations activity took place from June 26 to June 27, 2025, in Beijing and Shanghai, with participation from various investment firms [2][7][8]

Group 1 - The "2025 Nanshan Respiratory Health Forum" was held in Guangzhou, gathering leading experts in the field of respiratory health to discuss future developments [1] - The forum featured the launch of the "Beisi Probe-type Respiratory Confocal Endoscope (nCLE)", a high-end diagnostic device developed by Jingwei Vision, which addresses traditional diagnostic blind spots [2][4] - The nCLE has received approval as the only domestic probe-type respiratory confocal endoscope and has been recognized by the Ministry of Industry and Information Technology for its technological achievements [2][5] Group 2 - Professor Fu Ling delivered a keynote speech on the journey of domestic confocal endoscopes from technical exploration to clinical application, highlighting the challenges faced and the successful breakthroughs achieved by Jingwei Vision [5] - The nCLE technology enables real-time imaging at the cellular level, significantly improving early cancer detection rates and has been included in the 2024 national screening guidelines for esophageal and gastric cancers [5] - The nCLE provides new diagnostic pathways for lung cancer and acute rejection after lung transplantation, enhancing diagnostic accuracy and supporting clinical decision-making [7] Group 3 - Jingwei Vision launched a public welfare project to support early cancer patients, which will provide assistance to eligible patients across the country after they complete insurance reimbursements [7] - The company has established a complete autonomous industrial chain for confocal endoscopes, aiming to contribute to the future of precise respiratory diagnosis and support the "Healthy China" strategy [8]